ProQR Therapeutics (PRQR) announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
- ProQR Highlights RNA Innovations in Upcoming Event
- ProQR Therapeutics price target raised to $8 from $5 at JMP Securities
- ProQR Therapeutics Highlights Q3 2024 Financial Results
- ProQR Therapeutics price target raised to $10 from $5 at H.C. Wainwright
- ProQR Therapeutics price target raised to $4 from $2.50 at Chardan